^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway

Excerpt:
Antitumor efficacy of GDC-0980 was investigated in vivo in 3 xenograft models in combination with DTX:...(ii) A549 is a NSCLC model that contains an activating K-RAS mutation and is negative for LKB1 protein expression,...the combination of GDC-0980 and DTX resulted in tumor regressions in all 3 xenograft model evaluated...
Secondary therapy:
docetaxel
DOI:
10.1158/1535-7163.MCT-11-0446